Trial Profile
An Open-Label, Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Sun Pharma Global FZE
- 21 Mar 2023 Results assessing safety outcomes from a real-world study of tildrakizumab in patients with psoriasis presented at the American Academy of Dermatology annual Meeting 2023
- 21 Mar 2023 Results assessing the long-term effectiveness measured by clinical improvement and disease severity after 64 weeks of treatment with tildrakizumab under real-world conditions presented at the American Academy of Dermatology annual Meeting 2023.
- 21 Mar 2023 Results assessing primary outcome of improvement in health-related quality of life (HRQoL) from a real-world study of tildrakizumab. presented at the American Academy of Dermatology annual Meeting 2023